Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. IART.NASDAQ

Integra LifeSciences Holdings (IART NASDAQ) stock market data APIs

$31.77 0.34(1.1%) as of July 26, 2024
Price chart is built with Anychart

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Integra LifeSciences Holdings Financial Data Overview

31.43
31.77
-
32.19
30.82
22.36-46.09
2 485 M
61.8235
78 800 K
1 530 M
1.11
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'IART',
Type: 'Common Stock',
Name: 'Integra LifeSciences Holdings',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000BZJQL8',
ISIN: NULL,
CUSIP: NULL,
CIK: '917520',
EmployerIdNumber: '51-0317849',
FiscalYearEnd: 'December',
IPODate: '1995-08-16',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Medical Devices',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Integra LifeSciences Holdings Fundamental Data is available in our Financial Data APIs

  • Net Revenue 1 530 M
  • EBITDA 363 M
  • Earnings Per Share 0.51
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Integra LifeSciences Holdings Earnings via APIs

  • Latest Release 2024-07-29
  • EPS/Forecast 0.62

Get Integra LifeSciences Holdings End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Integra LifeSciences Holdings latest news via APIs

Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

The market expects Inari Medical, Inc. (NARI) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus ou...

Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline

Integra LifeSciences (IART) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook ...
Do you have any questions?
support@eodhistoricaldata.com